Amgen INC (AMGN) — 10-Q Filings

All 10-Q filings from Amgen INC. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Amgen's Q3 Earnings Soar on Strong Product Sales, R&D Spikes — Nov 5, 2025 Risk: medium
Amgen Inc. reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 12.4% to $9.557 billion for
Amgen Q2 Sales Climb on Strong Product Demand — Aug 6, 2025 Risk: medium
AMGEN INC reported product sales of $6.85 billion for the second quarter of 2025, an increase from $6.50 billion in the second quarter of 2024. Total revenues f
Amgen Q1 2025 Update: Financials and Product Performance — May 2, 2025 Risk: low
Amgen Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements include details on common stock, A2.
Amgen Inc. Q3 2024 Results Filed — Oct 31, 2024 Risk: low
Amgen Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing indicates financial activities and product sales fo
Amgen Inc. Files 10-Q for Q2 2024 — Aug 7, 2024 Risk: low
Amgen Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial statements and business operations are detailed in this 10-Q
Amgen Inc. Files 10-Q for Q1 2024 — May 3, 2024 Risk: medium
AMGEN INC (AMGN) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Amgen Inc. reported its Q1 2024 financial results on May 3, 2024. The filing cover

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX